microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy.
microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy.
复制标题
DOI：
10.1186/s12575-018-0082-9
复制
发表时间：
2018
影响因子：
6.4
通讯作者：
Yang X
中科院分区：
文献类型：
--
作者：
Howard EW;Yang X
由于对标准一线内分泌治疗的新发和获得性耐药是雌激素受体阳性（ER+）乳腺癌患者日益增长的临床挑战，因此了解耐药机制对于开发新的治疗策略以预防治疗耐药和改善患者结局至关重要。microRNAs（miRNAs）对多种致癌途径的广泛的转录后调节作用已被充分证明。特别是，据报道，几种miRNA通过与ESR 1 mRNA的3' UTR直接结合来抑制ERα表达，这可以赋予对雌激素/ERα靶向治疗的抗性。反过来，雌激素/ERα激活可以调节miRNA表达，这可能有助于ER+乳腺癌的发生。鉴于报道的ER+乳腺癌中miRNA的致癌和肿瘤抑制功能，特异性miRNA的靶向调节正在成为治疗ER+乳腺癌和显著改善患者对内分泌疗法的反应性的有希望的策略。在这篇综述中，我们强调了主要的miRNA-ER调控机制的背景下，ER+乳腺癌，以及关键的miRNAs，有助于内分泌治疗耐药或敏感性。总的来说，这一对当前文献的全面综述揭示了与miRNA调控机制和新的miRNA靶点相关的临床应用和挑战，这些靶点可能具有潜在的治疗ER+乳腺癌的翻译价值。
As de novo and acquired resistance to standard first line endocrine therapies is a growing clinical challenge for estrogen receptor-positive (ER+) breast cancer patients, understanding the mechanisms of resistance is critical to develop novel therapeutic strategies to prevent therapeutic resistance and improve patient outcomes. The widespread post-transcriptional regulatory role that microRNAs (miRNAs) can have on various oncogenic pathways has been well-documented. In particular, several miRNAs are reported to suppress ERα expression via direct binding with the 3’ UTR of ESR1 mRNA, which can confer resistance to estrogen/ERα-targeted therapies. In turn, estrogen/ERα activation can modulate miRNA expression, which may contribute to ER+ breast carcinogenesis. Given the reported oncogenic and tumor suppressor functions of miRNAs in ER+ breast cancer, the targeted regulation of specific miRNAs is emerging as a promising strategy to treat ER+ breast cancer and significantly improve patient responsiveness to endocrine therapies. In this review, we highlight the major miRNA-ER regulatory mechanisms in context with ER+ breast carcinogenesis, as well as the critical miRNAs that contribute to endocrine therapy resistance or sensitivity. Collectively, this comprehensive review of the current literature sheds light on the clinical applications and challenges associated with miRNA regulatory mechanisms and novel miRNA targets that may have translational value as potential therapeutics for the treatment of ER+ breast cancer.
登录
查看更多内容
影响因子：
14.9
作者：
Bhat-Nakshatri P;Wang G;Collins NR;Thomson MJ;Geistlinger TR;Carroll JS;Brown M;Hammond S;Srour EF;Liu Y;Nakshatri H
通讯作者：
Nakshatri H
影响因子：
11.2
作者：
Bacci, Marina;Giannoni, Elisa;Morandi, Andrea
通讯作者：
Morandi, Andrea
DOI：
10.1073/pnas.0906947106
发表时间：
2009-09-15
影响因子：
11.1
作者：
Castellano, Leandro;Giamas, Georgios;Stebbing, Justin
通讯作者：
Stebbing, Justin
影响因子：
3.2
作者：
Di Leva G;Cheung DG;Croce CM
通讯作者：
Croce CM
影响因子：
168.9
作者：
Davies, C.;Godwin, J.;Gray, R.;Clarke, M.;Darby, S.;McGale, P.;Wang, Y. C.;Peto, R.;Pan, H. C.;Cutter, D.;Taylor, C.;Ingle, J.
通讯作者：
Ingle, J.